PR

Prestige Biologics Co., Ltd.

A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.

334970 | KO

Overview

Corporate Details

ISIN(s):
KR7334970001
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명1로 197, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Prestige Biologics Co., Ltd. is a global biopharmaceutical Contract Development and Engineering Manufacturing Organization (CDEMO) offering end-to-end solutions for the entire lifecycle of antibody-based therapeutics and other biologics. The company provides a full suite of services, from initial cell line and process development to analytical testing and manufacturing of drug substances and products for both clinical trials and commercial supply. Operating within GMP-compliant facilities, Prestige Biologics also supports clients with secondary packaging, logistics, and transportation for clinical trials, positioning itself as an integrated partner for biopharmaceutical innovators.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Audit Report / Information
사업보고서 (2025.06)
Korean 493.5 KB
2025-09-18 00:00
Audit Report / Information
감사보고서제출
Korean 18.5 KB
2025-09-15 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 176.8 KB
2025-09-12 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 25.6 KB
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 148.4 KB
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 20.3 KB
2025-08-13 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.8 KB
2025-07-31 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 13.4 KB
2025-06-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-26 00:00
Regulatory News Service
투자판단관련주요경영사항 (바이오의약품 위탁생산 계약 진행의 건)
Korean 8.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.0 MB
2025-03-28 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 6.5 KB
2025-03-28 00:00
Board/Management Information
대표이사변경
Korean 9.0 KB
2025-03-17 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.1 KB

Automate Your Workflow. Get a real-time feed of all Prestige Biologics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prestige Biologics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prestige Biologics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.